RATIONALE: Metabolic syndrome (MetS) has consistently been identified as an adverse effect of long-term treatment with atypical antipsychotics (AAPs) such as clozapine. Elevated serum homocysteine concentration has been found to act as an independent risk factor for MetS, and catechol-O-methyltransferase (COMT) catalyzes the homocysteine metabolism. We accordingly hypothesized that COMT dysregulation may confer the susceptibility to MetS induced by AAPs, potentially in a gender-specific manner, because the interaction effects of COMT and gender have been consistently reported. OBJECTIVES: This study aimed at determining the prevalence and influence of COMT on MetS among a population undergoing long-term clozapine treatment. METHODS: A total of 468 schizophrenia patients taking clozapine were divided into two groups, those experiencing MetS and non-MetS. We genotyped three functional variants (rs4633, rs4680, and rs4818) in COMT and measured the serum levels of fasting homocysteine, glucose, triglyceride (TG), and high-density lipoprotein cholesterol. RESULTS: MetS was found in 202/468 (43.2 %) of all the patients, with 40.2 % prevalence (138/343) in males and 51.2 % (64/125) in females. Patients with MetS had notably higher metabolic parameters than those without MetS. The mean levels of homocysteine in patients with MetS were significantly higher than those without MetS. We found a positive association between the rs4680 polymorphism and the serum triglyceride levels (corrected P = 0.024). Further analysis revealed that the rs4680 Met allele was significantly associated with increased triglyceride levels among female patients (P = 0.009), but not among males (P = 0.07). CONCLUSIONS: Our findings suggest a potential association between rs4680 in COMT and elevated TG levels, particularly among female patients.
RATIONALE: Metabolic syndrome (MetS) has consistently been identified as an adverse effect of long-term treatment with atypical antipsychotics (AAPs) such as clozapine. Elevated serum homocysteine concentration has been found to act as an independent risk factor for MetS, and catechol-O-methyltransferase (COMT) catalyzes the homocysteine metabolism. We accordingly hypothesized that COMT dysregulation may confer the susceptibility to MetS induced by AAPs, potentially in a gender-specific manner, because the interaction effects of COMT and gender have been consistently reported. OBJECTIVES: This study aimed at determining the prevalence and influence of COMT on MetS among a population undergoing long-term clozapine treatment. METHODS: A total of 468 schizophreniapatients taking clozapine were divided into two groups, those experiencing MetS and non-MetS. We genotyped three functional variants (rs4633, rs4680, and rs4818) in COMT and measured the serum levels of fasting homocysteine, glucose, triglyceride (TG), and high-density lipoprotein cholesterol. RESULTS: MetS was found in 202/468 (43.2 %) of all the patients, with 40.2 % prevalence (138/343) in males and 51.2 % (64/125) in females. Patients with MetS had notably higher metabolic parameters than those without MetS. The mean levels of homocysteine in patients with MetS were significantly higher than those without MetS. We found a positive association between the rs4680 polymorphism and the serum triglyceride levels (corrected P = 0.024). Further analysis revealed that the rs4680 Met allele was significantly associated with increased triglyceride levels among female patients (P = 0.009), but not among males (P = 0.07). CONCLUSIONS: Our findings suggest a potential association between rs4680 in COMT and elevated TG levels, particularly among female patients.
Authors: Francesco Papaleo; Lucy Erickson; Guangping Liu; Jingshan Chen; Daniel R Weinberger Journal: Proc Natl Acad Sci U S A Date: 2012-11-19 Impact factor: 11.205
Authors: Seunghyong Ryu; Sohee Oh; Eun-Young Cho; Hee Jung Nam; Jae Hyun Yoo; Taesung Park; Yeon Ho Joo; Jun Soo Kwon; Kyung Sue Hong Journal: Am J Med Genet B Neuropsychiatr Genet Date: 2011-10-11 Impact factor: 3.568
Authors: Jofre Tenorio-Laranga; Pekka T Männistö; Maria Karayiorgou; Joseph A Gogos; J Arturo García-Horsman Journal: Biochem Pharmacol Date: 2009-02-21 Impact factor: 5.858
Authors: Vicki L Ellingrod; Del D Miller; Stephan F Taylor; Jessica Moline; Timothy Holman; Jane Kerr Journal: Schizophr Res Date: 2007-10-31 Impact factor: 4.939
Authors: Rowan Saloner; Maria J Marquine; Erin E Sundermann; Suzi Hong; John Allen McCutchan; Ronald J Ellis; Robert K Heaton; Igor Grant; Mariana Cherner Journal: J Acquir Immune Defic Syndr Date: 2019-08-15 Impact factor: 3.731
Authors: Amy L Pasternak; Kristen M Ward; Jasmine A Luzum; Vicki L Ellingrod; Daniel L Hertz Journal: Physiol Genomics Date: 2017-09-08 Impact factor: 3.107